{
  "id": 10637764,
  "title": "Pharming shares fall after CEO steps down over strategy dispute",
  "url": "https://urgent.news/2026/09/29/pharming-shares-fall-after-ceo-steps-down-over-strategy-dispute",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-09-29T07:28:13.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/stock-market-news/pharming-shares-fall-after-ceo-steps-down-over-strategy-dispute-93CH-4921686"
  },
  "original_language": "en",
  "account": "Biotechnology firm Pharming Group witnessed a significant drop in its shares, plunging by up to 6.5% on Tuesday, following the unexpected resignation of its CEO, Fabrice Chouraqui, with immediate effect. The dispute arose from a strategic disagreement between Chouraqui and the board of directors. In the wake of Chouraqui's departure, the shares recovered slightly, closing 1.63% lower at €0.905, as opposed to Monday's closing price of €0.920, according to Trading Economics data as of 03:27 ET (07:27 GMT).\n\nPharming, a company engaged in the development of therapies for rare immune and genetic disorders, revealed that Chouraqui and the board had coordinated the transition process in response to their discussions about the execution of the company's strategic objectives. To fill the leadership vacuum, Chief Commercial Officer Leverne Marsh and Chief Financial Officer Kenneth Lynard were appointed as interim co-CEOs, effective immediately. Marsh would be entrusted with managing patient-centric operations, while Lynard would be responsible for handling global corporate functions. The board subsequently initiated a search process to identify a permanent chief executive.\n\nDespite the upheaval, Pharming affirmed that its strategic direction and pipeline remained unaffected by the leadership transition. This report, generated with the assistance of artificial intelligence and subsequently reviewed by an editor, aimed to provide a comprehensive account of the events, adhering to the rules of factual reporting and avoiding speculation or conjecture.",
  "summary": null,
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}